本文来源：时代财经时代财经获悉，3月31日晚间，北海康成-B（01228.HK）发布2024年年度业绩。财报显示，北海康成，取得收益约为8510万元，同比减少约17.3%，较2023年减少580万元；年内亏损4.43亿元，同比亏损增加16.84%。截至报告期内，北海康成现金及银行结余约为1050万元。目前，北海康成已有艾度硫酸酯酶β（商品名：海芮思）、氯马昔巴特口服液（商品名：迈芮倍）等多款产品...
Source Link本文来源：时代财经时代财经获悉，3月31日晚间，北海康成-B（01228.HK）发布2024年年度业绩。财报显示，北海康成，取得收益约为8510万元，同比减少约17.3%，较2023年减少580万元；年内亏损4.43亿元，同比亏损增加16.84%。截至报告期内，北海康成现金及银行结余约为1050万元。目前，北海康成已有艾度硫酸酯酶β（商品名：海芮思）、氯马昔巴特口服液（商品名：迈芮倍）等多款产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.